Business / Finance

RSS

Endomagnetics reveals new brand identity Endomag

Endomagnetics is revealing a new brand identity that accurately reflects its position as a global leader in the development of devices for cancer care based on the application of advanced magnetic technologies.

15 Dec 2014

Anavex Life Sciences qualifies to trade on OTCQX

OTC Markets Group Inc., operator of Open, Transparent and Connected financial marketplaces, today announced that Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS), and various types of cancer, has qualified to trade on OTCQX, the best marketplace for established, global and growth companies.

14 Dec 2014

Leica Biosystems, Mayo Clinic partner to develop next generation of cytogenetics imaging software

Leica Biosystems and Mayo Clinic's Department of Laboratory Medicine and Pathology announced today a collaboration to develop the next generation of cytogenetics imaging software. The new tool will optimize software workflow and improve the overall user experience for cytogenetics imaging technicians.

14 Dec 2014

Champions reports decrease in revenue for second quarter of 2015

Champions Oncology, Inc., engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second quarter ended October 31, 2014.

14 Dec 2014

HudsonAlpha buys Illumina HiSeq X Ten sequencing system

HudsonAlpha Institute for Biotechnology today announced it has purchased the HiSeq X Ten sequencing system manufactured by Illumina, Inc. The technology will enable HudsonAlpha to produce and analyze genomic data faster and at a lower cost. The purchase stems from the Institute's commitment to research programs for genomics excellence in patient care.

From Illumina, Inc. 14 Dec 2014

Abbott acquires control of Veropharm for $305 million

Abbott today announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer.

12 Dec 2014

Claritas, NextCODE Health partner to bring global leadership in pediatric medicine, sequence analysis

To rapidly expand the use and power of genomic sequencing for diagnosing and treating rare diseases, Claritas Genomics and NextCODE Health today announced a strategic partnership bringing together global leadership in pediatric medicine and sequence analysis. Claritas Genomics, affiliated with Boston Children's Hospital, is a CLIA-certified clinical laboratory serving the DNA-based diagnostic testing needs of children's hospitals that admit hundreds of thousands of patients with genetic disorders every year.

11 Dec 2014

GI Partners completes acquisition of 9911 Belward Campus Drive

GI Partners today announced that it has completed the acquisition of 9911 Belward Campus Drive located in Rockville, Maryland. The acquisition was made through TechCore, LLC, which is a $1 billion discretionary core real estate fund managed by GI Partners.

11 Dec 2014

Diplomat announces new partnership with Novation through Hospital Specialty Rx Program

Diplomat, the nation's largest independent specialty pharmacy, has announced a new partnership with Novation through their Hospital Specialty Rx Program.

11 Dec 2014

Plymouth University receives £1.2M in funding to support capital investment for teaching facilities

Plymouth University has received funding in excess of £1.2M from the Higher Education Funding Council for England to support capital investment for teaching facilities in existing and proposed laboratories, at the headquarters of Plymouth University Peninsula Schools of Medicine and Dentistry (PUPSMD), Plymouth Science Park.

10 Dec 2014

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.

10 Dec 2014

Spark Therapeutics, Pfizer partner to develop SPK-FIX for potential treatment of hemophilia B

Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating genetic diseases, announced today that it has entered into a global collaboration with Pfizer Inc. for the development and potential commercialization of SPK-FIX, a development program advancing proprietary, bio-engineered adeno-associated virus (AAV) vectors for the potential treatment of hemophilia B.

8 Dec 2014

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2). Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates.

8 Dec 2014

BRI signs license agreement with SOBI for Kineret (anakinra)

Baylor Research Institute, the research arm of the Baylor Scott & White Health, announced that it has signed an agreement with Swedish Orphan Biovitrum AB (Sobi) to non-exclusively license Baylor's patents pertaining to the treatment of Systemic Onset Juvenile Idiopathic Arthritis (SJIA or SOJIA) using interleukin-1 (IL-1) beta antagonists.

6 Dec 2014

Tecomet completes acquisition of Symmetry Medical's OEM Solutions business

Tecomet Inc., a Genstar Capital portfolio company and precision contract manufacturer supporting the medical device and aerospace industries, announced today that it has completed the previously announced acquisition of Symmetry Medical's OEM Solutions business. This acquisition creates the largest orthopedic contract manufacturer in the world with 18 facilities located in five countries on three continents.

5 Dec 2014

Henry Schein's Board of Directors authorize $300 million share repurchase program

Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, announced today that its Board of Directors has authorized the repurchase of up to $300 million of shares of the Company's common stock.

5 Dec 2014

CareCore, MedSolutions complete merger agreement

CareCore National, LLC and MedSolutions, Inc., two leading providers of Specialty Benefits Management (SBM) services to managed care organizations and risk-bearing provider organizations, today announced the completion of a merger that will help advance the companies' collective commitment to containing healthcare costs and achieving quality medical outcomes.

4 Dec 2014

Welch Allyn, LKC Technologies sign distribution agreement for RETeval DR screening device

Welch Allyn, a leading medical diagnostic device company that delivers pragmatic innovation at the point of care, and LKC Technologies, Inc., the worldwide leader in visual electrophysiology and inventor of the RETeval DR diabetic retinopathy assessment device announced an exclusive distribution agreement.

4 Dec 2014

New collaborative project aims to generate 3% productivity boost at Australian pharmaceutical sites

META, a collaborative network of high potential manufacturing businesses and researchers, has today announced a collaborative project between Hospira, GlaxoSmithKline and CSL to generate a targeted 3% productivity boost with an estimated return on investment of up to $2.4M dollars at Australian pharmaceutical sites.

4 Dec 2014

BTG agrees to acquire PneumRx for $475 million

PneumRx, Inc., a leader in the field of interventional pulmonology, today announced that it has signed an agreement to be acquired by BTG Plc in a deal worth up to $475 million, based on an initial consideration of $230 million and up to $245 million in performance-related milestone payments.

4 Dec 2014

Business / Finance

Endomagnetics reveals new brand identity Endomag

Anavex Life Sciences qualifies to trade on OTCQX

Leica Biosystems, Mayo Clinic partner to develop next generation of cytogenetics imaging software

Champions reports decrease in revenue for second quarter of 2015

HudsonAlpha buys Illumina HiSeq X Ten sequencing system

Abbott acquires control of Veropharm for $305 million

Claritas, NextCODE Health partner to bring global leadership in pediatric medicine, sequence analysis

GI Partners completes acquisition of 9911 Belward Campus Drive

Diplomat announces new partnership with Novation through Hospital Specialty Rx Program

Plymouth University receives £1.2M in funding to support capital investment for teaching facilities

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Spark Therapeutics, Pfizer partner to develop SPK-FIX for potential treatment of hemophilia B

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

BRI signs license agreement with SOBI for Kineret (anakinra)

Tecomet completes acquisition of Symmetry Medical's OEM Solutions business

Henry Schein's Board of Directors authorize $300 million share repurchase program

CareCore, MedSolutions complete merger agreement

Welch Allyn, LKC Technologies sign distribution agreement for RETeval DR screening device

New collaborative project aims to generate 3% productivity boost at Australian pharmaceutical sites

BTG agrees to acquire PneumRx for $475 million

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News